{
    "2021-03-30": [
        [
            {
                "time": "2023-10-10",
                "original_text": "U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine",
                "features": {
                    "keywords": [
                        "FDA",
                        "AbbVie",
                        "Atogepant",
                        "New Drug Application",
                        "Preventive Treatment",
                        "Migraine"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}